Wolverine Asset Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-700
| Closed | -$13K | – | 2133 |
|
|
2023
Q3 | $13K | Hold |
700
| – | – | ﹤0.01% | 1427 |
|
|
2023
Q2 | $7.74K | Buy |
700
+400
| +133% | +$5.57K | ﹤0.01% | 1420 |
|
|
2023
Q1 | $4.03K | Sell |
300
-99,200
| -100% | -$1.72M | ﹤0.01% | 1575 |
|
|
2022
Q4 | $1.23M | Hold |
99,500
| – | – | 0.01% | 690 |
|
|
2022
Q3 | $1.39M | Hold |
99,500
| – | – | 0.02% | 679 |
|
|
2022
Q2 | $1.37M | Sell |
99,500
-300
| -0.3% | -$4.8K | 0.01% | 669 |
|
|
2022
Q1 | $1.62M | Sell |
99,800
-134,000
| -57% | -$2.1M | 0.02% | 577 |
|
|
2021
Q4 | $3.81M | Buy |
233,800
+2,200
| +0.9% | +$37.1K | 0.04% | 373 |
|
|
2021
Q3 | $3.44M | Buy |
231,600
+1,600
| +0.7% | +$25.6K | 0.03% | 357 |
|
|
2021
Q2 | $4.59M | Sell |
230,000
-8,200
| -3% | -$163K | 0.04% | 287 |
|
|
2021
Q1 | $5.5M | Sell |
238,200
-2,400
| -1% | -$66.9K | 0.05% | 228 |
|
|
2020
Q4 | $5.94M | Buy |
240,600
+24,000
| +11% | +$795K | 0.04% | 239 |
|
|
2020
Q3 | $8.98M | Buy |
216,600
+38,100
| +21% | +$1.75M | 0.08% | 159 |
|
|
2020
Q2 | $8.55M | Buy |
178,500
+69,400
| +64% | +$5.36M | 0.09% | 168 |
|
|
2020
Q1 | $6.87M | Sell |
109,100
-93,600
| -46% | -$8.41M | 0.1% | 161 |
|
|
2019
Q4 | $25.1M | Sell |
202,700
-3,000
| -1% | -$269K | 0.29% | 76 |
|
|
2019
Q3 | $13.7M | Buy |
205,700
+88,400
| +75% | +$5.94M | 0.17% | 111 |
|
|
2019
Q2 | $9.33M | Buy |
117,300
+55,200
| +89% | +$4.94M | 0.12% | 146 |
|
|
2019
Q1 | $6.95M | Buy |
62,100
+12,900
| +26% | +$1.41M | 0.09% | 178 |
|
|
2018
Q4 | $4.96M | Buy |
49,200
+31,800
| +183% | +$3.3M | 0.06% | 290 |
|
|
2018
Q3 | $2.2M | Buy |
+17,400
| New | +$1.84M | 0.03% | 559 |
|
|
2018
Q1 | – | Sell |
-41,000
| Closed | -$2.4M | – | 1743 |
|
|
2017
Q4 | $2.4M | Sell |
41,000
-11,100
| -21% | -$700K | 0.02% | 452 |
|
|
2017
Q3 | $3.02M | Buy |
52,100
+36,200
| +228% | +$3.9M | 0.03% | 365 |
|
|
2017
Q2 | $1.93M | Sell |
15,900
-21,400
| -57% | -$2.48M | 0.02% | 452 |
|
|
2017
Q1 | $4.22M | Buy |
37,300
+7,400
| +25% | +$864K | 0.07% | 250 |
|
|
2016
Q4 | $3.25M | Buy |
29,900
+23,700
| +382% | +$2.82M | 0.04% | 310 |
|
|
2016
Q3 | $1.02M | Buy |
+6,200
| New | +$977K | 0.02% | 564 |
|
Wolverine Asset Management's ICPT Position: Q1 2023 in Review
Wolverine Asset Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2023, closing a stake of 17,680 shares — an estimated $306K sold.
Wolverine Asset Management first reported a position in ICPT in Q4 2017 and held it in 6 quarters. The position peaked at $2.25M in Q2 2021. 144 funds tracked by Wall St. Rank hold ICPT as of Q1 2023.
- Wolverine Asset Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Wolverine Asset Management sold 17,680 Intercept Pharmaceuticals, Inc. shares in Q1 2023, an estimated $306K.
- Wolverine Asset Management first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2017 and held it in 6 quarters.
- Wolverine Asset Management's Intercept Pharmaceuticals, Inc. position peaked at $2.25M in Q2 2021.
- 144 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2023.
Based on Wolverine Asset Management's 13F filing for Q1 2023, filed 8 May 2023.